{"id":6226,"date":"2025-04-03T15:19:35","date_gmt":"2025-04-03T12:19:35","guid":{"rendered":"https:\/\/jordan-cardiac.org\/?p=6226"},"modified":"2025-04-03T15:19:35","modified_gmt":"2025-04-03T12:19:35","slug":"challenges-of-pharmacological-treatment-and-management-of-hyperkalemia-in-patients-on-raas-inhibitors-esc-congress-2025-highlights","status":"publish","type":"post","link":"https:\/\/jordan-cardiac.org\/en\/challenges-of-pharmacological-treatment-and-management-of-hyperkalemia-in-patients-on-raas-inhibitors-esc-congress-2025-highlights\/","title":{"rendered":"Challenges of pharmacological Treatment and Management of Hyperkalemia in Patients on RAAS Inhibitors \u2013 ESC Congress 2025 Highlights"},"content":{"rendered":"
Challenges of pharmacological Treatment and Management of Hyperkalemia in Patients on RAAS Inhibitors \u2013 ESC Congress 2025 Highlights<\/div>\n
1. Pharmacological Treatment of Hyperkalemia<\/span><\/div>\n
\u2022 ESC HF Guidelines: Potassium-lowering treatment with potassium binders should be initiated if serum potassium exceeds 5.0 mmol\/L. RAASi therapy should only be reduced or stopped if potassium exceeds 6.5 mmol\/L.<\/span><\/div>\n
\u2022 ACC HF Guidelines: Hyperkalemia is defined at a threshold of \u22655.5 mmol\/L.<\/span><\/div>\n
\u2022 KDIGO Guidelines(The term KDIGO stands for Kidney Disease Improving Global Outcomes. It is an international organization focused on improving outcomes for patients with kidney disease through evidence-based guidelines):\u00a0<\/span><\/div>\n
RAASi should not be discontinued unless hyperkalemia management strategies fail to normalize potassium levels.<\/div>\n
\u2022 Newer potassium binders like patiromer and SZC are effective for managing hyperkalemia while maintaining RAASi therapy.<\/span><\/div>\n
2. Potassium Binder Profiles<\/span><\/div>\n
\u2022 Older Potassium Binders (SPS, CPS) cause gastrointestinal side effects (e.g., constipation, nausea) and carry risks like ulcers and ischemia.<\/span><\/div>\n
\u2022 Patiromer: Exchanges potassium for calcium, making it safer for patients with conditions like hypertension, CKD, or HF.<\/span><\/div>\n
\u2022 SZC: Selectively binds potassium and has a rapid onset, making it ideal for quick potassium reduction.<\/span><\/div>\n
3. Recommendations for Hyperkalemia Management<\/span><\/div>\n
\u2022 Hyperkalemia is often asymptomatic and should be detected early through regular monitoring, particularly in high-risk patients.<\/span><\/div>\n
\u2022 Potassium binders should be initiated when potassium reaches \u22655.5 mmol\/L, confirmed by two tests.<\/span><\/div>\n
\u2022 Treatment should aim to normalize potassium levels (4.0\u20134.9 mmol\/L), as this range is associated with improved clinical outcomes.<\/span><\/div>\n
\u2022 ESC Recommendations: Hyperkalemia should be managed before reducing RAASi doses.<\/span><\/div>\n
\u2022 ACC Recommendations: If potassium cannot be maintained below 5.5 mmol\/L, MRAs should be discontinued.<\/span><\/div>\n
4. Consequences of Hyperkalemia<\/span><\/div>\n
\u2022 Hyperkalemia can lead to fatal cardiac arrhythmias and significantly increased hospitalization rates.<\/span><\/div>\n
5. Role of Potassium Binders<\/span><\/div>\n
\u2022 Newer potassium binders, like patiromer and SZC, play a crucial role in managing hyperkalemia, allowing the continued use of RAASi therapy without compromising safety.<\/span><\/div>\n
6. Emergency intervention is necessary for potassium levels exceeding 6.5 mmol\/L.<\/span><\/div>\n
7. Access to New Potassium Binders<\/span><\/div>\n
\u2022 Although patiromer and SZC are highly beneficial, their cost or availability may limit access for some patients, presenting a challenge to effective hyperkalemia management.<\/span><\/div>\n
<\/div>\n
This presentation was delivered during the ESC Congress 2025, focusing on the latest advancements and guidelines for the pharmacological treatment and management of hyperkalemia in patients receiving RAAS inhibitors.<\/div>\n","protected":false},"excerpt":{"rendered":"

Challenges of pharmacological Treatment and Management of Hyperkalemia in Patients on RAAS Inhibitors \u2013 ESC Congress 2025 Highlights 1. Pharmacological Treatment of Hyperkalemia \u2022 ESC HF Guidelines: Potassium-lowering treatment with potassium binders should be initiated if serum potassium exceeds 5.0 mmol\/L. RAASi therapy should only be reduced or stopped if potassium exceeds 6.5 mmol\/L. \u2022 […]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-6226","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/6226","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/comments?post=6226"}],"version-history":[{"count":1,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/6226\/revisions"}],"predecessor-version":[{"id":6227,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/6226\/revisions\/6227"}],"wp:attachment":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/media?parent=6226"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/categories?post=6226"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/tags?post=6226"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}